Corient Private Wealth
CORT icon

Corient Private Wealth’s Corcept Therapeutics CORT Stock Holding History

Corient Private Wealth’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
12,198
+6,345
+108% +$383K ﹤0.01% 1777
2026
Q1 		$233K Sell
5,853
-1,182
-17% -$44.2K ﹤0.01% 2466
2025
Q4 		$245K Buy
7,035
+600
+9% +$47.1K ﹤0.01% 2311
2025
Q3 		$535K Buy
6,435
+2,281
+55% +$165K ﹤0.01% 1761
2025
Q2 		$305K Buy
4,154
+40
+1% +$2.9K ﹤0.01% 1979
2025
Q1 		$470K Buy
4,114
+53
+1% +$3.23K ﹤0.01% 1627
2024
Q4 		$205K Buy
+4,061
New +$213K ﹤0.01% 2105

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth's CORT Position: Q2 2026 in Review

Corient Private Wealth increased its Corcept Therapeutics (CORT) stake by 108% in Q2 2026, buying an estimated $383K and bringing the position to 12,198 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1777.

Corient Private Wealth first reported a position in CORT in Q4 2024 and has held it in 7 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Corient Private Wealth held 12,198 shares of Corcept Therapeutics worth $1.06M as of Q2 2026.
  • Corient Private Wealth bought 6,345 Corcept Therapeutics shares in Q2 2026, an estimated $383K.
  • Corcept Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1777 holding.
  • Corient Private Wealth first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.